Where is APRINOIA located?

APRINOIA is headquartered in Taipei, Taiwan.

How many employees does APRINOIA have?

As of Jun 30, 2026, the latest employee count at APRINOIA is 22.

Is APRINOIA a funded company?

APRINOIA is a funded company, having raised a total of $51.1M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of APRINOIA?

APRINOIA's latest funding was a $***** Series C round on Dec 28, 2021, with participation from 5 investors.

Where does APRINOIA rank among its competitors?

APRINOIA ranks 115th amongst 526 active competitors, of which 178 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of APRINOIA?

APRINOIA's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Alchemab secured the most recent funding round in July, 2026.

APRINOIA - 2026 Company Profile, Team, Funding & Competitors

APRINOIA is a series C company based in Taipei (Taiwan), founded in 2015 by Ming-Kuei Jang. It operates as a Developer of diagnostics and therapeutics for neurodegenerative disorders. APRINOIA has raised $51.1M in funding from investors like KTB Network, Daiwa Corporate Investment and Yantai Dongcheng Biochemicals. The company has 526 active competitors, including 178 funded and 92 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.

Company Details

Developer of diagnostics and therapeutics for neurodegenerative disorders. The company focuses on the development of tau, alpha-synuclein, and other proteins that target neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. The company's lead candidate is APNmAb005 a humanized anti-tau antibody specifically targeting human tau aggregates found in tau-related diseases including Alzheimer's Disease.

Website: aprinoia.com
Email ID: *****@aprinoia.com

Key Metrics

Founded Year

2015

Location

Taipei, Taiwan

Stage

Series C

Total Funding

$51.1M in 5 rounds

Latest Funding Round

Series C, Dec 28, 2021, $*****

Investors

KTB Network & 11 more

Ranked

115^th among 526 active competitors

Employee Count

22 as on Jun 30, 2026

Similar Companies

Denali Therapeutics & 655 more

View APRINOIA's full profile

APRINOIA is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
APRINOIA THERAPEUTICS LLC CIN: 863658862 , United States, Active	Dec 31, 1999	-	2 (As on Dec 31, 2024)	-

APRINOIA has raised a total funding of $51.1M over 5 rounds. Its latest funding round was a Series C round on Dec 28, 2021 for $*****. 5 investors participated in its latest round. APRINOIA has 12 institutional investors.

Here is the list of recent funding rounds of APRINOIA:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 28, 2021	8586872	Series C	3722035	7415768	5723063	3215888
May 23, 2019	9568523	Grant (prize money)	8181411	7672034	2557786	The Michael J. Fox Foundation
Jan 16, 2018	7429840	Series B	8211852	6770040	Daiwa Corporate Investment & 1 more	ShangPharma & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of APRINOIA's funding rounds and investors

The founders of APRINOIA is Ming-Kuei Jang.

Here are the details of APRINOIA's key team members:

Ming-Kuei Jang: Founder & CEO of APRINOIA.

View details of APRINOIA's Founder profiles and Board Members

APRINOIA's employee count trend

APRINOIA has 22 employees as of Jun 26. Here is APRINOIA's employee count trend over the years:

Uncover APRINOIA's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of APRINOIA include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of APRINOIA, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Blackstone, Redmile Group & 17 others	67/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
8th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	65/100
9th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
115th	APRINOIA 2015, Taipei (Taiwan), Series C	Developer of diagnostics and therapeutics for neurodegenerative disorders	$51.1M	KTB Network, DT&Investment & 10 others	44/100